BillionToOne, Inc. (BLLN)
Nasdaq · Healthcare · Diagnostics & Research
$109.06+2.98%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $5.1B
- P/E (trailing)
- 173.1
- Forward P/E
- 73.4
- 52-week range
- $61.96 – $150.44
- 52-week change
- −2.79%
- EPS (trailing)
- $0.63
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $305M (+99.97%)
- Net income
- $7.5M
- Operating margin
- 5.3%
- Diluted EPS
- $0.14
- Free cash flow
- $15.7M
From the company’s annual report on SEC EDGAR.
About BillionToOne, Inc.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
Headquarters: Menlo Park, United States · 713 employees · billiontoone.com